February 2024:
Glycologix receives notice of second issued US patent

October 2023:
Glycologix Treats First Patient in Pilot Study of GLX-100 for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

May 2021:
Glycologix receives notice of issued US patent

January 2021:
Dan Deardorf joins Glycologix as President and Chief Executive Officer

October 2020:
Glycologix receives notice of issued Australian patent

July 2020:
Rich Heidebrecht, PhD, joins Glycologix as Vice President of Research and Development

June 2020:
Glycologix awarded $2M NIH SBIR Phase II grant

June 2018:
Glycologix awarded $287K NIH SBIR Phase I grant

March 2018:
Lead patent published under Patent Cooperation Treaty (PCT)

March 2016:
Glycologix founded